Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
MNKD - MannKind Corporation
Market Cap 1.21B P/E - EPS this Y 450.00% Ern Qtrly Grth -
Income 8.49M Forward P/E 30.60 EPS next Y 64.30% 50D Avg Chg 7.00%
Sales 224.6M PEG 0.86 EPS past 5Y - 200D Avg Chg 4.00%
Dividend N/A Price/Book N/A EPS next 5Y 35.60% 52W High Chg -20.00%
Recommedations 1.70 Quick Ratio 3.29 Shares Outstanding 272.32M 52W Low Chg 58.00%
Insider Own 1.52% ROA 4.97% Shares Float 267.89M Beta 1.34
Inst Own 49.10% ROE - Shares Shorted/Prior 30.87M/30.76M Price 4.59
Gross Margin 70.99% Profit Margin 3.78% Avg. Volume 2,709,170 Target Price 7.08
Oper. Margin 23.13% Earnings Date Aug 5 Volume 2,813,672 Change 2.23%
Healthcare | Biotechnology | United States
About MannKind Corporation

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

MannKind Corporation News
05/10/24 MannKind First Quarter 2024 Earnings: Beats Expectations
05/10/24 MannKind Corp (MNKD) Q1 2024 Earnings Call Transcript Highlights: A Quarter of Robust Growth ...
05/09/24 MannKind Corporation (NASDAQ:MNKD) Q1 2024 Earnings Call Transcript
05/09/24 Shareholders May Not Be So Generous With MannKind Corporation's (NASDAQ:MNKD) CEO Compensation And Here's Why
05/08/24 MannKind (MNKD) Q1 2024 Earnings Call Transcript
05/08/24 Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics
05/08/24 MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
05/08/24 MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
05/06/24 MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
05/01/24 MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
04/30/24 MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
04/29/24 MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
04/03/24 MannKind Repays Certain Debt Obligations
04/01/24 MannKind Corporation (NASDAQ:MNKD) down to US$1.2b market cap, but institutional owners may not be as affected after a year of 9.7% returns
03/29/24 Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?
03/26/24 MannKind Announces CFO Transition
03/25/24 Jim Cramer Says You Should Avoid These 11 Stocks
03/11/24 INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
03/05/24 MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
03/04/24 MannKind Corporation Announces Participation at Upcoming Conferences
MNKD Chatroom

User Image nomalarkey Posted - 37 seconds ago

$MNKD The life of a Mannkind investor....

User Image AboutTime2022 Posted - 5 minutes ago

$MNKD Yep! Always a strong buy 😊🐌🐌🐌🍿🍿

User Image Mann_Time Posted - 30 minutes ago

$MNKD VERY strong buy under 5. Just ask Ole Nate.. eh?

User Image MayorofMNKD Posted - 34 minutes ago

$MNKD …are we able to submit questions yet for the annual? I want to ask Mike if he plans on announcing a non obligatory stock repurchase plan for the next 2 years to send a message to the crooks of wallstreet

User Image Arielsquare04 Posted - 34 minutes ago

$MNKD if we can just get some shorts get exposed to some surprise good news off we go.

User Image BenYiju Posted - 35 minutes ago

$MNKD Welcome to the Thunderdome, Shorty, you’re gonna feel some pain!

User Image BenYiju Posted - 53 minutes ago

$MNKD Sorry, Shorty, this is the #MOASS!!! #IBelieveThatWeWillWin

User Image Iammakingmoney1555 Posted - 1 hour ago

$MNKD We believe there will be an explosion on the upside very soon and we are very excited and believe this will be our biggest money maker(trade) we've seen in years-GL

User Image Kuka Posted - 2 hours ago

$DJT Go DJT....and FJB :) Long $MNKD

User Image chazbruin2 Posted - 2 hours ago

$MNKD slow & steady back up 🆙 ⬆️

User Image NatesNotes Posted - 2 hours ago

Congrats to all who have hung in there with $MNKD despite all the reasons you've been given not to over the years - enjoy the duck rodeo (especially if it is your first) as it continues to play out! ;-) Cheers! #knowwhatyouown #factsmatter #MikehastwoGo

User Image mangothegreat Posted - 2 hours ago

$MNKD

User Image grampslol Posted - 2 hours ago

On topic 33 yr old $MNKD a trade for pennies cult stock. Over paid overbonused insiders, Flop Drug. Heavily owned by small time retail. Off topic This is einteresting "The manipulation of financial statements to commit fraud against investors or skirt regulation is a real and ongoing problem, costing billions of dollars each year. Managers may also "cook the books" in order to qualify for certain executive compensation that relies on certain financial performance metrics being met. Because generally accepted accounting standards can be flexible and open for interpretation by a company's management, fudging numbers can be difficult to detect. https://www.investopedia.com/articles/fundamental-analysis/financial-statement-manipulation.asp#How%20Financial%20Statements%20Are%20Manipulated

User Image WalterPayton Posted - 2 hours ago

$MNKD this is the reason for the sci fi market today

User Image clan Posted - 2 hours ago

@Outcomes "I'm not a cat." $GME $MNKD

User Image NoLumpyOatmeal Posted - 2 hours ago

$MNKD Someone tell @getalife that @clan needs an intervention. Interesting how @getalife only comments on posters who are not happy with the pps and yet ignores guys like @clan.

User Image nomalarkey Posted - 2 hours ago

$MNKD Can someone email Mike to ask him how many missed shots on goals he's taken so far and why not one has been made under his watch?

User Image getalife Posted - 2 hours ago

$MNKD gonna be a long day gramps,started early. Man what a freakin boring job you have.

User Image WalterPayton Posted - 3 hours ago

$MNKD irrational exuberance is alive and well except at mnkd

User Image Iammakingmoney1555 Posted - 3 hours ago

$MNKD We keep buying because we believe there will be + news soon but only for the trade, no long term hold on this dog. Have made good coin on trading this stock over the years-GL

User Image nomalarkey Posted - 3 hours ago

$MNKD is a meme stock. Here's the meme:

User Image Arielsquare04 Posted - 3 hours ago

$MNKD is the lqda uthr patent war over?

User Image WalterPayton Posted - 3 hours ago

$MNKD WS and the Markets are fuked up!

User Image Outcomes Posted - 3 hours ago

$MNKD $NRXP Viral moments, pounding shorts, and Roaring Kitties!! https://finance.yahoo.com/news/gamestop-shares-rocket-pounding-short-124927394.html

User Image nomalarkey Posted - 3 hours ago

$MNKD Let me be blunt. There were no pps target upgrades as one or two pumptards told us would happen. I wonder how the Chinese deal with pumptards?

User Image WalterPayton Posted - 3 hours ago

$MNKD we need a Roaring Kitty here!

User Image Outcomes Posted - 3 hours ago

$MNKD 'Our pulmonary team will be at Booth# 6 at the Fairmont Grand Del Mar. MannKind was recently granted Fast Track designation for its Phase 3 study of the potential of Clofazimine Inhalation Suspension (MNKD-101)' https://www.linkedin.com/posts/mannkind-corporation_mnkd-ntm-ntmlungdisease-activity-7195769767574581250-utQi?utm_source=share&utm_medium=member_desktop

User Image grampslol Posted - 3 hours ago

Ever so bullish Being Bearish $MNKD the cult stock with the flop diabetes drug approved in 2014.

User Image nomalarkey Posted - 3 hours ago

$MNKD SO, where there any price target upgraded from the existing ANALysts covering this steaming pile of turd that's been stuck in the mud for a decade?

User Image Mann_Time Posted - 3 hours ago

$MNKD 28 earnings calls for Castagna. 0 for 28. #PHENOMENAL

Analyst Ratings
Cantor Fitzgerald Overweight May 9, 24
Cantor Fitzgerald Overweight Mar 15, 24
Cantor Fitzgerald Overweight Feb 28, 24
HC Wainwright & Co. Buy Jan 4, 24
Wedbush Outperform Oct 10, 23
HC Wainwright & Co. Buy Aug 14, 23
Cantor Fitzgerald Overweight Aug 8, 23
HC Wainwright & Co. Buy May 11, 23
HC Wainwright & Co. Buy Feb 27, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Castagna Michael Chief Executive Offi.. Chief Executive Officer Dec 14 Sell 4 200,482 801,928 2,148,665 12/15/23
Castagna Michael Chief Executive Offi.. Chief Executive Officer Nov 01 Sell 4.25 10,000 42,500 2,349,147 11/02/23
Castagna Michael Chief Executive Offi.. Chief Executive Officer Oct 02 Sell 4.08 10,000 40,800 2,359,147 10/03/23
Castagna Michael Chief Executive Offi.. Chief Executive Officer Sep 01 Sell 4.61 10,000 46,100 2,436,039 09/05/23
Thomson David EVP Genl Counsel & S.. EVP Genl Counsel & Secretary Aug 27 Sell 4.78 8,100 38,718 798,835 08/28/23
Castagna Michael Chief Executive Offi.. Chief Executive Officer Aug 01 Sell 4.5686 10,000 45,686 2,496,735 08/01/23
Castagna Michael Chief Executive Offi.. Chief Executive Officer Jul 03 Sell 4.04 10,000 40,400 2,506,735 07/07/23
Castagna Michael Chief Executive Offi.. Chief Executive Officer Jun 01 Sell 4.5302 10,000 45,302 2,516,735 06/02/23
Castagna Michael Chief Executive Offi.. Chief Executive Officer May 25 Sell 4.55 150,000 682,500 2,526,735 05/26/23
Thomson David EVP Genl Counsel & S.. EVP Genl Counsel & Secretary May 22 Sell 4.68 95,576 447,296 735,263 05/24/23
Castagna Michael Chief Executive Offi.. Chief Executive Officer May 22 Sell 4.69 150,000 703,500 2,331,735 05/24/23
Binder Steven B. Chief Financial Offi.. Chief Financial Officer May 22 Sell 4.68 47,810 223,751 838,324 05/24/23
Castagna Michael Chief Executive Offi.. Chief Executive Officer May 05 Sell 4.00 10,000 40,000 2,020,128 05/05/23
Castagna Michael Chief Executive Offi.. Chief Executive Officer Apr 03 Sell 4.1287 10,000 41,287 2,030,128 04/05/23
Castagna Michael Chief Executive Offi.. Chief Executive Officer Mar 01 Sell 5.2748 10,000 52,748 2,040,128 03/03/23
Thomson David EVP Genl Counsel & S.. EVP Genl Counsel & Secretary Aug 27 Sell 3.67 7,000 25,690 726,035 08/29/22
Galindo Alejandro EVP Endocrine Busine.. EVP Endocrine Business Unit Aug 22 Sell 3.85 4,615 17,768 777,075 08/23/22
Binder Steven B. Chief Financial Offi.. Chief Financial Officer Jul 31 Buy 2.93 791 2,318 728,997 08/01/22
Castagna Michael Chief Executive Offi.. Chief Executive Officer Jul 31 Buy 2.93 3,147 9,221 2,084,486 08/01/22
Tross Stuart A Chief People & Workp.. Chief People & Workpl Officer Jul 31 Buy 2.93 4,581 13,422 830,650 08/01/22
Galindo Alejandro EVP Endocrine Busine.. EVP Endocrine Business Unit Jul 31 Buy 2.93 5,000 14,650 781,690 08/01/22
HOOPER ANTHONY C Director Director Feb 28 Buy 2.71 40,000 108,400 338,394 03/01/22
MUNDKUR CHRISTINE Director Director Feb 28 Buy 2.71 27,675 74,999 254,493 03/01/22
Galindo Alejandro Chief Commercial Off.. Chief Commercial Officer Jan 31 Buy 3.17 1,804 5,719 539,790 02/09/22
Castagna Michael Chief Executive Offi.. Chief Executive Officer Jan 31 Buy 3.17 1,804 5,719 1,505,098 02/09/22
Tross Stuart A Chief People & Workp.. Chief People & Workpl Officer Jan 31 Buy 3.17 2,254 7,145 622,785 02/09/22
Binder Steven B. Chief Financial Offi.. Chief Financial Officer Jan 31 Buy 3.17 711 2,254 534,178 02/02/22
Thomson David EVP Genl Counsel & S.. EVP Genl Counsel & Secretary Aug 27 Sell 4.64 4,100 19,024 567,391 08/27/21